Sirtex Medical Limited’s Post

Our team loves to get out in the field to engage with the community of professionals who are leveraging our products to deliver high-quality care. We're constantly striving to deliver top-tier innovation that has a positive impact on both patients and physicians, and in-person meetings are one of the ways we identify the priorities that matter most.

The LAVA® Liquid Embolic System has officially made it to New Hampshire! Dr. Vibhor Wadhwa, interventional radiologist with Southern New Hampshire Radiology Consultants at Elliot Hospital, performed a successful embolization using LAVA®, and our team is thrilled to see the expansion of this treatment option. Find the details on this New Hampshire first-use case here: https://lnkd.in/eW-Kg3ki

#CIO2024 was one for the books! Thank you Symposium on Clinical Interventional Oncology for a fantastic event and to all who stopped by our booth to chat with our team. To learn more about our LAVA® Liquid Embolic System and our SIR-Spheres® FLEXdose SELECT Delivery Program, visit our products page: https://bit.ly/47vNttZ

We're on the ground at #CIO2024 with Symposium on Clinical Interventional Oncology! You won't want to miss our symposium today at 12:15pm ET where Asad Baig, MD and Nima Kokabi, MD FRCPC will discuss optimizing SIR-Spheres® #Y90 resin microspheres for personalized treatment intent. Visit booth 205 for more Sirtex product information and find the full event details here: https://lnkd.in/eh3bfkdF

Our team had a fantastic week at #CIRSE2024! Thank you to the attendees who stopped to chat with us, the Cardiovascular and Interventional Radiological Society of Europe for hosting and our incredible Sirtex team for their commitment to sharing our latest updates - especially the approval of SIROS™ in the EU!

We're excited to announce the official European Union certification of SIR-Spheres® Y-90 resin microspheres according to the latest Medical Device Regulation (MDR)! In tandem with the announcement comes the European launch of our SIROS™ Delivery System, which expands regional #EMEA treatments options for unresectable hepatocellular carcinoma (HCC) and unresectable metastatic liver tumors from primary colorectal cancer (mCRC) in patients refractory to or intolerant of chemotherapy. The EU MDR places greater emphasis on patient safety measures, risk management, post-market surveillance, and comprehensive data collection for medical devices seeking European market access, and we are extremely proud to offer groundbreaking interventional oncology solutions that align with these standards. Learn how this impact is making a difference for both patients and physicians here: https://lnkd.in/ehXyXKC6

Join us for an expert webinar on Thursday, 9/26 at 7pm ET. Dr. Gary Siskin and Dr. Christopher Stark will be doing a case review and discussion on our LAVA® Liquid Embolic System. Follow the link to register: https://lnkd.in/dCB-W5iy

Our team is gearing up for #CIO2024 with Symposium on Clinical Interventional Oncology next week in Miami, Florida! Whether you're looking to chat with our team, receive hands-on device training or tune into a symposium featuring physicians and their thoughts on optimizing Y-90 treatment, you'll find it all at CIO 2024. Take a look at all of the places we'll be throughout the event so that you can learn about our interventional oncology solutions. 👇 Full event details here: https://lnkd.in/eh3bfkdF

Physicians across the U.S. have been utilizing our new SIR-Spheres® FLEXdose SELECT Delivery Program and embracing the flexibility it provides. Hear from Dr. Jerry Gibbs on both the patient and physician value that SELECT offers. Find more details here: https://lnkd.in/e5drVxK7